Loading
CD58 (Lymphocyte function-associated antigen 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.
Ligand of the T-lymphocyte CD2 glycoprotein. This interaction is important in mediating thymocyte interactions with thymic epithelial cells, antigen-independent and -dependent interactions of T-lymphocytes with target cells and antigen-presenting cells and the T-lymphocyte rosetting with erythrocytes. In addition, the LFA-3/CD2 interaction may prime response by both the CD2+ and LFA-3+ cells.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 2 cohorts (0 activating, 2 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Non-Hodgkin Lymphoma.
In plain words · CD58 (Lymphocyte function-associated antigen 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.
CD58 (Lymphocyte function-associated antigen 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.
Ligand of the T-lymphocyte CD2 glycoprotein.
No product in this corpus aims at CD58 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA CD58: RNA low tissue specificity; no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P19256; CIViC gene CD58; IntOGen CD58; Human Protein Atlas CD58 tissue; Open Targets ENSG00000116815 associations
First described 1987. Earliest sequence paper UniProt cites for the protein: Wallner B.P. et al, J. Exp. Med, 1987, "Primary structure of lymphocyte function-associated antigen 3 (LFA-3). The ligand of the T lymphocyte CD2 glycoprotein". Source.
Sources: HGNC HGNC:1688 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P19256 (protein name, function text, keywords and locations (REST API)); CIViC gene CD58 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); IntOGen CD58 (driver in 2 cohorts (Act 0, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Ligand of the T-lymphocyte CD2 glycoprotein. This interaction is important in mediating thymocyte interactions with thymic epithelial cells, antigen-independent and -dependent interactions of T-lymphocytes with target cells and antigen-presenting cells and the T-lymphocyte rosetting with erythrocytes. In addition, the LFA-3/CD2 interaction may prime response by both the CD2+ and LFA-3+ cells. Location: Cell membrane (UniProt). Locus 1p13.1 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
HPA CD58 tissue · HPA CD58 pathology · HPA protein class: CD markers
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CD58" OR ABSTRACT:"CD58" OR TITLE:"CD58 molecule" OR ABSTRACT:"CD58 molecule" OR TITLE:"Lymphocyte function-associated antigen 3" OR ABSTRACT:"Lymphocyte function-associated antigen 3" OR TITLE:"LFA3" OR ABSTRACT:"LFA3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD58, not a curated reading list.
Shares Clonal haematopoiesis (CHIP), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma), Epigenetic reprogramming, CIViC.
Shares Clonal haematopoiesis (CHIP), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma), Epigenetic reprogramming, CIViC.
Shares Clonal haematopoiesis (CHIP), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma), Epigenetic reprogramming, Non-Hodgkin lymphoma (all types).
Shares Clonal haematopoiesis (CHIP), CIViC, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Clonal haematopoiesis (CHIP), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma), Epigenetic reprogramming, Non-Hodgkin lymphoma (all types).
Shares Clonal haematopoiesis (CHIP), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma), Epigenetic reprogramming, Non-Hodgkin lymphoma (all types).
Shares Clonal haematopoiesis (CHIP), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma), Epigenetic reprogramming, Non-Hodgkin lymphoma (all types).
Shares Epigenetic reprogramming, CIViC, IntOGen, Diffuse large B-cell lymphoma.